Understanding MYC changes in aggressive B-cell lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how changes in the MYC gene affect the outlook for people with certain fast-growing lymphomas, including diffuse large B-cell lymphoma and high-grade B-cell lymphoma. It aims to better understand the tumor environment and how these patients respond to standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a specific type of fast-growing B-cell lymphoma (like diffuse large B-cell lymphoma or high-grade B-cell lymphoma).
- You must have a change in the MYC gene (like a translocation or extra copies) found by a FISH test.
- You have had standard chemotherapy as your first treatment, such as R-CHOP or similar.
- Your doctor must have a sample of your tumor tissue (a tissue block) available for extra testing.
- You are between 18 and 79 years old.
- You do not have lymphoma that started in the brain or certain other rare types like Burkitt lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a treatment sequence for people with high-risk diffuse large B-cell lymphoma (DLBCL) that includes loncastuximab plus rituximab, then DA-EPOCH-R. It aims to improve responses in patients whose lymphoma has specific high-risk features.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This study looks at a “Mixed Molecular Clinical Index” (MMCI), which combines test results from lymphoma tissue and clinical information. It aims to help better understand how diffuse large B-cell lymphoma behaves and how patients may respond to standard first-line treatment.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
This trial tests adding a drug called mosunetuzumab to standard chemotherapy for people with certain aggressive B-cell lymphomas. It aims to see if the combination works better than chemo alone.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.